| PP100122004799 |
Vera Therapeutics, Inc. |
VT-001 |
atacicept |
An anti-Bl.. |
IgA nephro.. |
Phase III, Phase III |
View Details
|
| PP090320006133 |
VistaGen Therapeutics, Inc. (since Feb 2023), Pherin Pharmaceuticals, Inc. |
Aloradine, PH94B |
4-androstadienol; 4,16-androstadien-3β-ol; fasedienol |
A potent p.. |
Social anx.. |
Phase III |
View Details
|
| PP090320006134 |
VistaGen Therapeutics, Inc. (since Feb 2023), Pherin Pharmaceuticals, Inc. |
PH284 |
|
|
Wasting sy.. |
Phase II |
View Details
|
| PP090320006135 |
VistaGen Therapeutics, Inc. (since Feb 2023), Pherin Pharmaceuticals, Inc. |
PH15 |
|
|
Cognitive .. |
Phase II, Phase II |
View Details
|
| PP090320006136 |
VistaGen Therapeutics, Inc. (since Feb 2023), Pherin Pharmaceuticals, Inc. |
PH10 |
itruvone |
A chemorec.. |
Major depr.. |
Phase II |
View Details
|
| PP090923006286 |
Vivoryon Therapeutics AG (since Jun 2019), Probiodrug AG |
PQ912 |
varoglutamstat |
Inhibition.. |
Diabetic k.. |
Phase II completed, Phase II |
View Details
|
| PP090323007715 |
Vanda Pharmaceuticals Inc. |
Hetlioz®, VEC-162 |
tasimelteon |
A dual mel.. |
Non-24-hou.. |
Approved, NDA, NDA |
View Details
|
| PP141128012612 |
Worg Pharmaceuticals Co., Ltd.(since Sep 2021), Apitope Technology Bristol Ltd. |
WP1302, ATX-GD-59 |
|
A thyrotro.. |
Hyper-thyr.. |
Phase I completed |
View Details
|
| PP150113012687 |
Vyriad (since Mar 2016), Omnis Pharma Inc. |
Voyager-V1 |
vesicular stomatitis virus engineered |
|
Non-small .. |
Phase II, Phase II, Phase II |
View Details
|
| PP150113012688 |
Vyriad (since Mar 2016), Omnis Pharma Inc. |
Voyager-V1 |
vesicular stomatitis virus engineered |
|
Multiple m.. |
Phase I completed, Phase I completed, Phase I completed |
View Details
|